BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) and Genelux (NASDAQ:GNLX – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Volatility and Risk
BioMarin Pharmaceutical has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Genelux has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for BioMarin Pharmaceutical and Genelux, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioMarin Pharmaceutical | 1 | 6 | 15 | 3 | 2.80 |
| Genelux | 1 | 0 | 2 | 1 | 2.75 |
Insider and Institutional Ownership
98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares BioMarin Pharmaceutical and Genelux”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioMarin Pharmaceutical | $3.22 billion | 3.44 | $348.90 million | ($0.10) | -571.30 |
| Genelux | $10,000.00 | 8,821.80 | -$32.15 million | ($0.86) | -2.27 |
BioMarin Pharmaceutical has higher revenue and earnings than Genelux. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BioMarin Pharmaceutical and Genelux’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioMarin Pharmaceutical | -0.52% | 5.58% | 3.51% |
| Genelux | N/A | -205.85% | -138.79% |
Summary
BioMarin Pharmaceutical beats Genelux on 10 of the 15 factors compared between the two stocks.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.
About Genelux
Genelux Corporation is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. The company’s lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, genetically modified oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating an immune response against cancer. Genelux is evaluating Olvi-Vec in combination with other treatments across multiple solid-tumor indications. Its clinical development efforts have included ovarian cancer, where the candidate is being studied in patients with advanced or recurrent disease, as well as other potential applications in cancers such as colorectal and lung cancer.
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
